A Study of Glycemic Control in Left Ventricular Assist

Launched by MAYO CLINIC · Jun 28, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how well a common test for blood sugar control, called hemoglobin A1c, works for patients who have a left ventricular assist device (LVAD) and type 2 diabetes. The study aims to see if this blood test gives accurate information about blood sugar levels compared to a continuous glucose monitor (CGM), which tracks blood sugar levels all the time. The researchers want to find out if using a CGM can help patients better manage their blood sugar, especially to avoid low blood sugar episodes.

To participate in this study, you need to have had an LVAD implanted after 2010 and be diagnosed with type 2 diabetes. You should also be able to use a smartphone app to share your blood sugar data. If you meet these criteria and are willing to take part, you will be monitored for three months to see how well your blood sugar is controlled. This study is currently recruiting participants, and it’s open to both men and women aged 65 to 74. Your involvement could help improve understanding of diabetes management in patients with LVADs.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Prior implantation of contemporary, centrifugal flow LVAD (HeartWare or HeartMate 3) at any time after 2010
• • Diagnosis of type II diabetes mellitus
• • Any antihyperglycemic regimen
• • Greater than 3 months out from LVAD implantation
• • Capable of utilizing smartphone device for LibreLink app for uploading glycemic data
• • Patients may be enrolled who have preexisting CGM in place.
• Exclusion Criteria:
• • Type I diabetics
• • Unable to return at 3 month evaluation
• • Unwillingness to participate